Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075146 | 0.75 | L3MBTL1 (0.44) | MEN1KMT2AALDH1A1HTTCYP2A6 | |
| SCHEMBL4612464 | 0.72 | ESR1 (0.59) | MEN1KMT2AALDH1A1HTTESR1 | |
| SCHEMBL4612461 | 0.72 | ESR1 (0.59) | MEN1KMT2AALDH1A1HTTESR1 | |
| SCHEMBL30853842 | 0.70 | AURKA (0.53) | ALDH1A1HTTCYP2A6MAOAMAOB | |
| SCHEMBL13508393 | 0.68 | MEN1 (0.38) | MEN1KMT2AALDH1A1ESR1MAPT | |
| SCHEMBL780794 | 0.68 | HTR7 (0.45) | MEN1KMT2AMAOAMAOBESR1 | |
| SCHEMBL5945849 | 0.67 | ESR1 (0.53) | MEN1KMT2AALDH1A1ESR1CYP19A1 | |
| SCHEMBL3075856 | 0.67 | TSHR (0.42) | MEN1KMT2AALDH1A1HTTCYP2A6 | |
| SCHEMBL55433 | 0.66 | ESR1 (0.74) | MEN1KMT2AALDH1A1HTTESR1 | |
| Benzene SCHEMBL27868814 | 0.66 | ESR1 (0.74) | MEN1KMT2AALDH1A1HTTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149800-B2 | Method for producing ruthenium catalyst and method for producing alkyl group—or alkenyl group-substituted compound using ruthenium catalyst | KYOTO UNIVERSITY (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9149800-B2 | Method for producing ruthenium catalyst and method for producing alkyl group—or alkenyl group-substituted compound using ruthenium catalyst | KYOTO UNIVERSITY (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150165433-A1 | METHOD FOR PRODUCING RUTHENIUM CATALYST AND METHOD FOR PRODUCING ALKYL GROUP- OR ALKENYL GROUP-SUBSTITUTED COMPOUND USING RUTHENIUM CATALYST | KYOTO UNIVERSITY (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150165433-A1 | METHOD FOR PRODUCING RUTHENIUM CATALYST AND METHOD FOR PRODUCING ALKYL GROUP- OR ALKENYL GROUP-SUBSTITUTED COMPOUND USING RUTHENIUM CATALYST | KYOTO UNIVERSITY (JP) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150165433-A1 | METHOD FOR PRODUCING RUTHENIUM CATALYST AND METHOD FOR PRODUCING ALKYL GROUP- OR ALKENYL GROUP-SUBSTITUTED COMPOUND USING RUTHENIUM CATALYST | ADH5, ADH1A, ADH1C | MEN1 3085/4885KMT2A 2086/4885ALDH1A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.